Clinical trial
Perifosine in Treating Patients With Locally Advanced, Unresectable, or…
NCT00059982 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00059982 |
|---|---|
| Title | Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer |
| Official title | Phase II Trial Of Perifosine In Locally Advanced, Unresectable Or Metastatic Pancreatic Adenocarcinoma |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | perifosine |
| Start date | Jul 1, 2003 |
| Completion | Aug 1, 2005 |
| First posted | May 7, 2003 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: